Diagnostic reagents company Immuno Concepts said on Wednesday that it has passed the Histofluor Rodent LKS Rodent Tissue Slides for manual and Image Navigator use through the US Food and Drug Administration's (FDA) 510(k) process.
Following the US FDA's clearance, Histofluor Rodent Tissue Slides are available in both mouse and rat substrates and can be read manually or scanned using the innovative Image Navigator automated microscope, added the company.
The company stated the indirect immunofluorescent (IIF) test has long been the preferred method for determination of Anti-Mitochondrial Antibodies (AMA), Anti-Smooth Muscle Antibodies (ASMA) and Anti-Parietal Cell Antibodies. These autoantibodies are associated with several autoimmune diseases, including Pernicious Anemia or Autoimmune Gastritis, Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis.
According to the company, the same slides and reagents for the Histofluor Rodent Tissue Slides are used regardless of whether the slides are read manually or scanned on the Image Navigator.
In conjunction, the previously US FDA-Cleared Image Navigator eliminates the usual tedious labor of the IIF test, while still allowing the laboratory professional to control the interpretation and reporting of these tests, concluded the company.
Roivant to announce Q3 2026 financial results
HUTCHMED reports positive Phase III results for sovleplenib in wAIHA
Physiomics secures follow-on UK contract for Phase 2 study support
Amgen's UPLIZNA receives US FDA approval
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
AstraZeneca to invest USD2bn in major Maryland manufacturing expansion
European Commission approves Celltrion's Remsima IV liquid formulation
TIRmed Pharma partners with Bachem to advance production of atopic dermatitis therapy
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Vascarta and CUNY report positive preclinical results in glioblastoma treatment